Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.

Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A.

Clin Cancer Res. 2018 Apr 17. doi: 10.1158/1078-0432.CCR-17-3509. [Epub ahead of print]

PMID:
29666300
2.

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L.

Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Review.

PMID:
29209572
3.

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M.

Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Review.

4.

Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System.

Pupuleku A, Costa-García M, Farré D, Hengel H, Angulo A, Muntasell A, López-Botet M.

Front Immunol. 2017 Oct 24;8:1317. doi: 10.3389/fimmu.2017.01317. eCollection 2017.

5.

Life-Long Neurogenic Activity of Individual Neural Stem Cells and Continuous Growth Establish an Outside-In Architecture in the Teleost Pallium.

Furlan G, Cuccioli V, Vuillemin N, Dirian L, Muntasell AJ, Coolen M, Dray N, Bedu S, Houart C, Beaurepaire E, Foucher I, Bally-Cuif L.

Curr Biol. 2017 Nov 6;27(21):3288-3301.e3. doi: 10.1016/j.cub.2017.09.052. Epub 2017 Oct 26.

6.

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.

Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.

Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18.

PMID:
28821558
7.

Impact of Zygosity on Bimodal Phenotype Distributions.

Holst-Hansen T, Abad E, Muntasell A, López-Botet M, Jensen MH, Trusina A, Garcia-Ojalvo J.

Biophys J. 2017 Jul 11;113(1):148-156. doi: 10.1016/j.bpj.2017.05.010.

PMID:
28700913
8.

Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles.

López-Montañés M, Alari-Pahissa E, Sintes J, Martínez-Rodríguez JE, Muntasell A, López-Botet M.

J Immunol. 2017 Jul 15;199(2):656-665. doi: 10.4049/jimmunol.1601574. Epub 2017 Jun 19.

PMID:
28630095
9.

Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation.

López-Botet M, Vilches C, Redondo-Pachón D, Muntasell A, Pupuleku A, Yélamos J, Pascual J, Crespo M.

Front Immunol. 2017 Feb 16;8:166. doi: 10.3389/fimmu.2017.00166. eCollection 2017. Review.

10.

Targeting NK-cell checkpoints for cancer immunotherapy.

Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I.

Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23. Review.

PMID:
28236750
11.

Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.

Redondo-Pachón D, Crespo M, Yélamos J, Muntasell A, Pérez-Sáez MJ, Pérez-Fernández S, Vila J, Vilches C, Pascual J, López-Botet M.

J Immunol. 2017 Jan 1;198(1):94-101. Epub 2016 Dec 2.

12.

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.

Sánchez-Martínez D, Lanuza PM, Gómez N, Muntasell A, Cisneros E, Moraru M, Azaceta G, Anel A, Martínez-Lostao L, Villalba M, Palomera L, Vilches C, García Marco JA, Pardo J.

Front Immunol. 2016 Oct 27;7:454. eCollection 2016.

13.

Development of the adaptive NK cell response to human cytomegalovirus in the context of aging.

López-Botet M, Muntasell A, Martínez-Rodríguez JE, López-Montañés M, Costa-García M, Pupuleku A.

Mech Ageing Dev. 2016 Sep;158:23-6. doi: 10.1016/j.mad.2016.06.010. Epub 2016 Jun 24. Review.

PMID:
27349430
14.

Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers.

Baía D, Pou J, Jones D, Mandelboim O, Trowsdale J, Muntasell A, López-Botet M.

Eur J Immunol. 2016 Jul;46(7):1681-90. doi: 10.1002/eji.201546149. Epub 2016 Jun 2.

15.

Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets.

Muntasell A, Pupuleku A, Cisneros E, Vera A, Moraru M, Vilches C, López-Botet M.

J Immunol. 2016 May 1;196(9):3818-27. doi: 10.4049/jimmunol.1502438. Epub 2016 Mar 18.

16.

Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.

Muntasell A, López-Botet M.

Clin Cancer Res. 2016 Apr 15;22(8):1831-3. doi: 10.1158/1078-0432.CCR-15-3168. Epub 2016 Feb 22.

17.

Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.

Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M.

Mult Scler. 2016 May;22(6):741-52. doi: 10.1177/1352458515601215. Epub 2015 Sep 11.

PMID:
26362897
18.

NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation.

Moraru M, Black LE, Muntasell A, Portero F, López-Botet M, Reyburn HT, Pandey JP, Vilches C.

J Immunol. 2015 Aug 15;195(4):1676-84. doi: 10.4049/jimmunol.1500872. Epub 2015 Jul 15.

19.

Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Sánchez-Martínez D, Azaceta G, Muntasell A, Aguiló N, Núñez D, Gálvez EM, Naval J, Anel A, Palomera L, Vilches C, Marzo I, Villalba M, Pardo J.

Oncoimmunology. 2015 Jan 9;4(3):e991613. eCollection 2015 Mar.

20.

Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus.

Costa-Garcia M, Vera A, Moraru M, Vilches C, López-Botet M, Muntasell A.

J Immunol. 2015 Mar 15;194(6):2715-24. doi: 10.4049/jimmunol.1402281. Epub 2015 Feb 9.

Supplemental Content

Loading ...
Support Center